Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.

ABSTRACT:

Aims

Large outcome studies demonstrated a reduction of heart failure hospitalization or cardiovascular death in patients with chronic heart failure (CHF). The renin-angiotensin system (RAS) is a key player in fluid and sodium regulation. The classic angiotensin-converting enzyme-angiotensin II-angiotensin-1 receptor axis (Ang I-ACE-Ang II receptor axis) is predominantly angiotensin II (Ang-II) induced and promotes vasoconstriction. In contrast, the angiotensin-converting-enzyme-2-angiotensin-(1-7)-Mas axis (Mas-axis) is mediated by the metabolites angiotensin-1-7 (Ang-(1-7)) and angtiotensin-1-5 (Ang-(1-5)) and exerts cardioprotective effects.

Methods

We previously investigated the effect of empagliflozin on the systemic haemodynamic in patients with stable CHF (NYHA II-III)

SUBMITTER: Bosch A 

PROVIDER: S-EPMC10192237 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature